The disclosure relates to a class of 6-cycloalkyl-pyrazolopyrimidinone (a ketone of a pyrazolopyrimidine structure) compounds according to the drawing, wherein R1 and D are defined in the specification. The compounds of the invention show PDE9 inhibiting properties. These compounds can then be used as the active entity of medicaments, or for the manufacture of medicaments, for the treatment of conditions concerning deficits in perception, concentration, learning or memory, including Alzheimers disease and schizophrenia.